This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
5-MeO-MiPT: Difference between revisions
>Dextromethorphan legality switzerölamd |
>Krekel m Updated the info about SNRI action |
||
| (18 intermediate revisions by 10 users not shown) | |||
| Line 4: | Line 4: | ||
'''5-Methoxy-N-methyl-N-isopropyltryptamine''' (also known as '''5-MeO-MiPT''' and '''moxy''') is a lesser-known [[psychoactive class::psychedelic]] substance of the [[chemical class::tryptamine]] class. 5-MeO-MiPT is chemically related to tryptamines like [[5-MeO-DMT]] and [[5-MeO-DiPT]]. It produces its psychoactive effects through activity at [[serotonin]] [[receptors]] in the brain. | '''5-Methoxy-N-methyl-N-isopropyltryptamine''' (also known as '''5-MeO-MiPT''' and '''moxy''') is a lesser-known [[psychoactive class::psychedelic]] substance of the [[chemical class::tryptamine]] class. 5-MeO-MiPT is chemically related to tryptamines like [[5-MeO-DMT]] and [[5-MeO-DiPT]]. It produces its psychoactive effects through activity at [[serotonin]] [[receptors]] in the brain. | ||
The synthesis and pharmacology of 5-MeO-MiPT was first reported in 1985 by David Repke and Alexander Shulgin.<ref>Repke | The synthesis and pharmacology of 5-MeO-MiPT was first reported in 1985 by David Repke and Alexander Shulgin.<ref name="Repke1985">{{cite journal|last1=Repke|first1=D. B.|last2=Grotjahn|first2=D. B.|last3=Shulgin|first3=A. T.|author-link3=Alexander Shulgin|title=Psychotomimetic N-methyl-N-isopropyltryptamines. Effects of variation of aromatic oxygen substituents|journal=Journal of Medicinal Chemistry|year=1985|volume=28|issue=7|pages=892–896|doi=10.1021/jm00145a007|pmid=4009612|issn=0022-2623|eissn=1520-4804|oclc=39480771}}</ref> Its effects in humans was documented in Shulgin's book [[TiHKAL]] ("Tryptamines I Have Known and Loved"). | ||
Anecdotal reports describe 5-MeO-MiPT's effects as highly [[stimulating]] and mildly [[entactogenic]], lacking in typical psychedelic visual distortions. Many users report strong physical and tactile effects that serve to [[increased libido|enhance libido]] and sexual pleasure. An unpleasant "body load" is also often reported at common to high doses, marked by muscle tension and nausea. | Anecdotal reports describe 5-MeO-MiPT's effects as highly [[stimulating]] and mildly [[entactogenic]], lacking in typical psychedelic visual distortions. Many users report strong physical and tactile effects that serve to [[increased libido|enhance libido]] and sexual pleasure. An unpleasant "body load" is also often reported at common to high doses, marked by muscle tension and nausea. | ||
| Line 13: | Line 13: | ||
5-MeO-MiPT, or 5-methoxy-N-methyl-N-isopropyltryptamine, is a synthetic indole alkaloid molecule of the [[tryptamine]] class. Tryptamines share a core structure comprised of a bicylic indole heterocycle attached at R<sub>3</sub> to an amino group via an ethyl side chain. 5-MeO-MiPT is substituted at R<sub>5</sub> of its indole heterocycle with a methoxy (MeO) functional group CH<sub>3</sub>O−; it also contains a methyl group and an isopropyl chain bound to the terminal amine R<sub>N</sub> of its tryptamine backbone (MiPT). | 5-MeO-MiPT, or 5-methoxy-N-methyl-N-isopropyltryptamine, is a synthetic indole alkaloid molecule of the [[tryptamine]] class. Tryptamines share a core structure comprised of a bicylic indole heterocycle attached at R<sub>3</sub> to an amino group via an ethyl side chain. 5-MeO-MiPT is substituted at R<sub>5</sub> of its indole heterocycle with a methoxy (MeO) functional group CH<sub>3</sub>O−; it also contains a methyl group and an isopropyl chain bound to the terminal amine R<sub>N</sub> of its tryptamine backbone (MiPT). | ||
5-MeO-MiPT is the N-substituted isopropyl homologue of [[5-MeO-DMT]].<ref> | 5-MeO-MiPT is the N-substituted isopropyl homologue of [[5-MeO-DMT]].<ref name="TiHKAL">{{cite book|title=TiHKAL: The Continuation|title-link=TiHKAL|last1=Shulgin|first1=Alexander|last2=Shulgin|first2=Ann|author-link1=Alexander Shulgin|year=1997|publisher=Transform Press|location=United States|isbn=0-9630096-9-9|oclc=38503252|chapter-url=https://erowid.org/library/books_online/tihkal/tihkal40.shtml|chapter=#40. 5-MeO-MiPT}}</ref> | ||
==Pharmacology== | ==Pharmacology== | ||
{{Further|Serotonergic psychedelic}} | {{Further|Serotonergic psychedelic}} | ||
5-MeO-MiPT's [[psychedelic]] effects are believed to come from its efficacy at the [[Serotonin#The 5-HT system|5-HT<sub>2A</sub> receptor]] as a [[Agonist#Agonists|partial agonist]]<ref>The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain | 5-MeO-MiPT's [[psychedelic]] effects are believed to come from its efficacy at the [[Serotonin#The 5-HT system|5-HT<sub>2A</sub> receptor]] as a [[Agonist#Agonists|partial agonist]]<ref name="pmid17223101">{{cite journal|title=The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain|pmid=17223101|volume=559|issue=2–3|year=2007|pages=132-137|first1=F.|last1=Nagai|first2=R.|last2=Nonaka|first3=K.|last3=Satoh|first4=H.|last4=Kamimura|journal=European Journal of Pharmacology|issn=0014-2999|eissn=1879-0712|oclc=01568459|doi=10.1016/j.ejphar.2006.11.075}}</ref><ref name="Repke1985" /> and additional mechanisms of action such as the inhibition of [[MAOI|MAO]] (i.e. digestive enzymes in the stomach) have also been speculated upon, though this has yet to be demonstrated scientifically. While 5-MeO-MiPT binds most strongly to 5-HT1A receptors, It might act as a moderately potent serotonin-norepinephrine reuptake inhibitor<ref>{{cite journal | vauthors=((Ray, T. S.)) | journal=PLoS ONE | title=Correction: Psychedelics and the Human Receptorome | volume=5 | issue=3 | date=4 March 2010 | url=https://dx.plos.org/10.1371/annotation/e580a864-cf13-40c2-9bd9-b9687a6f0fe4 | issn=1932-6203 | doi=10.1371/annotation/e580a864-cf13-40c2-9bd9-b9687a6f0fe4}}</ref> but other studies have not found significant action at the monoamine transporters[https://www.sciencedirect.com/science/article/abs/pii/S0924977X16300426]. These mechanisms may help explain why there are many anecdotal reports of anti-depressant and anxiolytic effects from modest doses of this compound. For example, SNRIs such as venlafaxine are commonly prescribed to treat depression, and the 5-HT1A agonist buspirone is prescribed primarily for treatment of anxiety. | ||
==Subjective effects== | ==Subjective effects== | ||
| Line 23: | Line 23: | ||
{{Preamble/SubjectiveEffects}} | {{Preamble/SubjectiveEffects}} | ||
{{effects/base | {{effects/base | ||
|{{effects/physical| | |{{effects/physical| | ||
| Line 76: | Line 77: | ||
*'''[[Effect::Increased music appreciation]]''' | *'''[[Effect::Increased music appreciation]]''' | ||
*'''[[Effect::Emotion enhancement]]''' | *'''[[Effect::Emotion enhancement]]''' | ||
*'''[[Effect::Increased libido]]''' | *'''[[Effect::Increased libido]]''' - increased libido and significantly enhanced orgasms are reported | ||
*'''[[Effect::Memory suppression]]''' | *'''[[Effect::Memory suppression]]''' | ||
*'''[[Effect::Novelty enhancement]]''' | *'''[[Effect::Novelty enhancement]]''' | ||
| Line 98: | Line 99: | ||
*[https://www.erowid.org/experiences/subs/exp_5MeOMIPT.shtml Erowid Experience Vaults: 5-MeO-MiPT] | *[https://www.erowid.org/experiences/subs/exp_5MeOMIPT.shtml Erowid Experience Vaults: 5-MeO-MiPT] | ||
==Reagent results== | |||
Exposing compounds to the reagents gives a colour change which is indicative of the compound under test. The following test results are from [https://www.protestkit.eu/results/ ProTestKit]. | |||
{| class="wikitable" | |||
!5-MeO-MiPT | |||
!Marquis | |||
!Mecke | |||
!Mandelin | |||
!Liebermann | |||
!Ehrlich | |||
!Hofmann | |||
!Simon’s | |||
|- | |||
|Freebase | |||
|Orange - brown | |||
|Orange red | |||
|Deep greenish brown | |||
|Unknown | |||
|Purple | |||
|No reaction | |||
|No reaction | |||
|- | |||
|HCl | |||
|Orange - brown | |||
|Red - brown | |||
|Greenish brown | |||
|Brown | |||
|Violet - purple | |||
|Green | |||
|Unknown | |||
|} | |||
==Toxicity and harm potential== | ==Toxicity and harm potential== | ||
{{further|Research chemicals#Toxicity and harm potential|Responsible use #Hallucinogens}} | {{further|Research chemicals#Toxicity and harm potential|Responsible use #Hallucinogens}} | ||
Almost nothing is known about the long-term effects of 5-MeO-MiPT. Alongside of this, the exact toxic dosage is unknown. This is because 5-MeO-MiPT is a [[research chemical]] with very little history of human use. | |||
A preliminary study on mice has shown that a normal dose of 5-MeO-MiPT (0.27 mg/kg) was unable to produce any measurable toxic effects.<ref name=":0">Altuncı YA, Aydoğdu M, Açıkgöz E, Güven Ü, Düzağaç F, Atasoy A, Dağlıoğlu N, Annette Akgür S. [https://pubmed.ncbi.nlm.nih.gov/32936075/ New Psychoactive Substance 5-MeO-MiPT In vivo Acute Toxicity and Hystotoxicological Study.] Balkan Med J. 2021 Jan;38(1):34-42. [[wikipedia:Digital_object_identifier|doi]]:[https://doi.org/10.4274/balkanmedj.galenos.2020.2019.11.68 10.4274/balkanmedj.galenos.2020.2019.11.68] [[wikipedia:PubMed_Identifier|PMID]]: [https://pubmed.ncbi.nlm.nih.gov/32936075/ 32936075]; [https://en.wikipedia.org/wiki/PubMed_Central#PMCID PMCID]: [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc8909217/ PMC8909217]. | |||
<br /></ref> However, doses of 5-MeO-MiPT way above the normal dosage range (2.7 mg/kg) have been shown to produce cell toxicity by triggering programmed cell death in the brain, liver and kidneys. The extent of the damage, if it occurs in other bodily tissues as well and how it is caused is not known yet. | |||
Anecdotal evidence from people within the community who have tried 5-MeO-MiPT suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). [https://www.google.com/ Independent research] should always be done to ensure that a combination of two or more substances is safe before consumption. | Anecdotal evidence from people within the community who have tried 5-MeO-MiPT suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). [https://www.google.com/ Independent research] should always be done to ensure that a combination of two or more substances is safe before consumption. | ||
| Line 107: | Line 143: | ||
It is strongly recommended that one use [[responsible drug use|harm reduction practices]] when using this drug. | It is strongly recommended that one use [[responsible drug use|harm reduction practices]] when using this drug. | ||
===Tolerance and addiction potential=== | ===Tolerance and addiction potential=== | ||
5-MeO-MiPT is [[Addiction potential::not habit-forming]] and the desire to use it can actually decrease with use. It is most often self-regulating. | 5-MeO-MiPT is [[Addiction potential::not habit-forming]], and the desire to use it can actually decrease with use. It is most often self-regulating. | ||
Tolerance to the effects of 5-MeO-MiPT | Tolerance to the effects of 5-MeO-MiPT is built [[Time to full tolerance::almost immediately after ingestion]]. After that, it takes about [[Time to half tolerance::3 days]] for the tolerance to be reduced to half and [[Time to zero tolerance::7 days]] to be back at baseline (in the absence of further consumption). 5-MeO-MiPT presents cross-tolerance with [[Cross-tolerance::all [[psychedelic]]s]], meaning that after the consumption of 5-MeO-MiPT all psychedelics will have a reduced effect. | ||
===Dangerous interactions=== | ===Dangerous interactions=== | ||
| Line 115: | Line 151: | ||
{{DangerousInteractions/5-MeO-xxT}} | {{DangerousInteractions/5-MeO-xxT}} | ||
There are no known deaths from 5-MeO-MiPT but, as a [[monoamine]] [[reuptake inhibitor]] (MRI)<ref | There are no known deaths from 5-MeO-MiPT but, as a [[monoamine]] [[reuptake inhibitor]] (MRI)<ref name="pmid17223101" />, injury could occur when excessive doses are taken or when it is taken with drugs such as [[MAOIs]], [[RIMA]]s, [[stimulant]]s and any substance which act as a [[releasing agent]] or [[reuptake inhibitor]] of [[neurotransmitters]] such as [[serotonin]] and [[dopamine]].<ref>{{cite journal|title=Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity|url=https://bjanaesthesia.org/article/S0007-0912(17)34956-5/fulltext|doi=10.1093/bja/aei210|last=Gillman|first=P. K.|journal=British Journal of Anaesthesia|volume=95|issue=4|year=2005|pages=434–441|issn=0007-0912|eissn=1471-6771|oclc=01537271}}</ref> | ||
==Legal status== | ==Legal status== | ||
*'''Brazil''': 5-MeO-MiPT is illegal to produce, sell, or possess as it is listed on Portaria SVS/MS nº 344.<ref>http://portal.anvisa.gov.br/documents/10181/3115436/%281%29RDC_130_2016_.pdf/fc7ea407-3ff5-4fc1-bcfe-2f37504d28b7</ref> | *'''Austria''': 5-MeO-MiPT is illegal to possess, produce and sell under the NPSG (''Neue Psychoaktive Substanzen Gesetz'').<ref>[https://www.ris.bka.gv.at/GeltendeFassung.wxe?Abfrage=Bundesnormen&Gesetzesnummer=20007605 Gesamte Rechtsvorschrift für Neue-Psychoaktive-Substanzen-Gesetz] ''(in german). Bundeskriminalamt Österreich. Retrieved April 13, 2023.''</ref> However, offenders with no intent to distribute will likely not have to face prosecution. | ||
*'''China''': 5-MeO-MiPT is controlled as a Category I psychotropic substance and is illegal to sell, buy, import, export, and manufacture.<ref>Erowid China Psychoactive Law Update: September 2015 | https://www.erowid.org/psychoactives/law/countries/china/china_law_2015_09_27_list_of_newly_controlled_chemicals.pdf</ref> | *'''Brazil''': 5-MeO-MiPT is illegal to produce, sell, or possess as it is listed on Portaria SVS/MS nº 344.<ref>{{cite web|url=http://portal.anvisa.gov.br/documents/10181/3115436/%281%29RDC_130_2016_.pdf/fc7ea407-3ff5-4fc1-bcfe-2f37504d28b7|title=RESOLUÇÃO DA DIRETORIA COLEGIADA - RDC N° 130, DE 2 DE DEZEMBRO DE 2016|publication-date=December 5, 2016|publisher=Agência Nacional de Vigilância Sanitária (ANVISA) [Brazilian Health Regulatory Agency (ANVISA)]|language=pt}}</ref> | ||
*'''Finland''': 5-MeO-MiPT was banned in Finland in December 2014.<ref> | *'''China''': 5-MeO-MiPT is controlled as a Category I psychotropic substance and is illegal to sell, buy, import, export, and manufacture.<ref>{{cite web|title=Erowid China Psychoactive Law Update: September 2015|url=https://www.erowid.org/psychoactives/law/countries/china/china_law_2015_09_27_list_of_newly_controlled_chemicals.pdf|access-date=September 29, 2020|publisher=Erowid}}</ref> | ||
*'''Germany''': 5-MeO-MiPT is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019.<ref>{{cite web|url= | *'''Finland''': 5-MeO-MiPT was banned in Finland in December 2014.<ref>{{cite web|title=1130/2014: Valtioneuvoston asetus: kuluttajamarkkinoilta kielletyistä psykoaktiivisista aineista|publication-date=December 19, 2014|url=https://www.erowid.org/psychoactives/law/countries/finland/finland_law1_2014.pdf|work=Suomen Säädöskokoelma|language=fi}}</ref> | ||
*'''Germany''': 5-MeO-MiPT is controlled under the NpSG<ref>{{cite web|url=https://www.gesetze-im-internet.de/npsg/anlage.html|title=Anlage NpSG|publisher=Bundesamt für Justiz [Federal Office of Justice]|access-date=December 10, 2019|language=de}}</ref> (''New Psychoactive Substances Act'') as of July 18, 2019.<ref>{{cite web|url=http://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl119s1083.pdf|title=Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes|publisher=Bundesanzeiger Verlag|work=Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27|pages=1083-1094|publication-date=July 17, 2019|language=de|issn=0341-1095}}</ref> Production and import with the aim to place it on the market, administration to another person, placing it on the market and trading is punishable. Possession is illegal but not punishable.<ref>{{cite web|url=https://www.gesetze-im-internet.de/npsg/__4.html|title=§ 4 NpSG|publisher=Bundesamt für Justiz [Federal Office of Justice]|access-date=December 10, 2019|language=de}}</ref><ref>{{cite web|url=https://www.gesetze-im-internet.de/npsg/__3.html|title=§ 3 NpSG|publisher=Bundesamt für Justiz [Federal Office of Justice]|access-date=December 10, 2019|language=de}}</ref> The legislator considers it possible that orders of 4-HO-MiPT are punishable as an incitement to place it on the market.<ref>{{cite web|url=http://dip21.bundestag.de/dip21/btd/18/085/1808579.pdf|title=Gesetzentwurf der Bundesregierung: Entwurf eines Gesetzes zur Bekämpfung der Verbreitung neuer psychoaktiver Stoffe|page=20|date=May 30, 2016|id=Drucksache 18/8579|publisher=Deutscher Bundestag|language=de}}</ref> | |||
*'''Japan''': 5-MeO-MiPT is controlled as a "Designated Substance" (Shitei-Yakubutsu) by the Pharmaceutical Affairs Law, making it illegal to possess or sell.{{citation needed}} | *'''Japan''': 5-MeO-MiPT is controlled as a "Designated Substance" (Shitei-Yakubutsu) by the Pharmaceutical Affairs Law, making it illegal to possess or sell.{{citation needed}} | ||
*'''Latvia''': 5-MeO-MiPT is a Schedule I drug in Latvia.<ref>Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem | *'''Latvia''': 5-MeO-MiPT is a Schedule I drug in Latvia.<ref>{{cite web|url=http://likumi.lv/doc.php?id=121086|title=Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem|publisher=VSIA Latvijas Vēstnesis|access-date=January 1, 2020|publication-date=November 10, 2005|language=lv}}</ref> | ||
*'''New Zealand''': 5-MeO-MiPT is an analogue of DMT which makes it a Class C controlled drug in New Zealand.<ref>http://www.legislation.govt.nz/act/public/1975/0116/latest/whole.html#DLM436576</ref> | *'''Luxembourg''': 5-MeO-MiPT is not cited in the list of prohibited substances<ref>{{Citation | title=Loi du 19 février 1973 concernant la vente de substances médicamenteuses et la lutte contre la toxicomanie. | url=https://legilux.public.lu/eli/etat/leg/loi/1973/02/19/n1/jo}}</ref>. Therefore, it is still a legal substance. | ||
*'''New Zealand''': 5-MeO-MiPT is an analogue of DMT which makes it a Class C controlled drug in New Zealand.<ref>{{cite web|url=http://www.legislation.govt.nz/act/public/1975/0116/latest/whole.html#DLM436576|title=Schedule 1: Class A controlled drugs|access-date=September 19, 2020|work=Misuse of Drugs Act 1975|publisher=Parliamentary Counsel Office (PCO)}}</ref> | |||
*'''Romania''': 5-MeO-MiPT and other derivatives are illegal in Romania, as of January 2011.{{citation needed}} | *'''Romania''': 5-MeO-MiPT and other derivatives are illegal in Romania, as of January 2011.{{citation needed}} | ||
*'''Switzerland''': 5-MeO-MiPT is a controlled substance specifically named under Verzeichnis E.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref> | *'''Switzerland''': 5-MeO-MiPT is a controlled substance specifically named under Verzeichnis E.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref> | ||
*'''United Kingdom''': 5-MeO-MiPT is a Class A drug in the UK as it is an ether of the drug 5-HO-MiPT | *'''Turkey:''' 5-MeO-MiPT is classed as a drug and is illegal to possess, produce, supply, or import.<ref>Bakanlar Kurulu Kararı Karar Sayısı : 2013/4827 | https://free-ankara.org/wp-content/uploads/2017/09/BKK_2013_4827_28688.pdf</ref> | ||
*'''United States''': 5-MeO-MiPT is unscheduled in the United States. It may be considered an analogue of [[5-MeO-DiPT]], a Schedule I drug under the Controlled Substances Act. As such, the sale for human consumption or the use for illicit non-medical or industrial intents and purposes could be prosecuted as crimes under the Federal Analogue Act. | *'''United Kingdom''': 5-MeO-MiPT is a Class A drug in the UK as it is an ether of the drug 5-HO-MiPT, which is a Class A drug as a result of the tryptamine catch-all clause.<ref>{{cite web|title=Schedule 2: Part I: Class A Drugs|url=http://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I|work="Misuse of Drugs Act 1971"|access-date=August 20, 2020|publisher=UK Government}}</ref> | ||
**'''Florida''': 5-MeO-MiPT is a Schedule I drug in Florida.<ref>The 2015 Florida Statutes | *'''United States''': 5-MeO-MiPT is unscheduled in the United States. It may be considered an analogue of [[5-MeO-DiPT]], a Schedule I drug under the Controlled Substances Act. As such, the sale for human consumption or the use for illicit non-medical or industrial intents and purposes could be prosecuted as crimes under the Federal Analogue Act.<ref>https://www.law.cornell.edu/uscode/text/21/813</ref> | ||
**'''Louisiana''': 5-MeO-MiPT is a Schedule I drug (as of June 2013).<ref>5-MeO- | **'''Florida''': 5-MeO-MiPT is a Schedule I drug in Florida.<ref>{{cite web|title=The 2015 Florida Statutes - Chapter 893|url=http://leg.state.fl.us/statutes/index.cfm?App_mode=Display_Statute&URL=0800-0899/0893/0893.html|publisher=The Florida Legislature|access-date=July 18, 2020}}</ref> | ||
**'''Minnesota''': Minnesota banned a series of drugs including 5-MeO-MiPT.<ref> | **'''Louisiana''': 5-MeO-MiPT is a Schedule I drug (as of June 2013).<ref>{{cite web|title=5-MeO-MIPT: Legal Status|publisher=Erowid|url=https://www.erowid.org/chemicals/5meo_mipt/5meo_mipt_law.shtml|date=July 7, 2005|access-date=September 29, 2020}}</ref> | ||
**'''Minnesota''': Minnesota banned a series of drugs including 5-MeO-MiPT.<ref>{{cite web|title=2019 Minnesota Statutes|publisher=Office of the Revisor of Statutes|year=2019|access-date=September 29, 2020|url=https://www.revisor.mn.gov/statutes/?id=152.02}}</ref> | |||
==See also== | ==See also== | ||